Analysis published in ASN, highlighted compelling evidence that ERAs offer substantial therapeutic benefits for CKD patients.

For Micron Technology, the PE, PB, and PS ratios are all low compared to industry peers, indicating potential undervaluation.

HDFC Bank delivered its Q3 FY26 financial results on Saturday and it was broadly on expected lines. However, the stock ended ...

New analysis reveals the average proportion of authorities' council tax and general funds spent on adult and children's ...

Rule of 20 has misfired since 2021; learn why 2026 signals may mislead, plus outlook on SPY vs bonds/gold and productivity ...

This impressive performance has been fueled by heightened demand for its customized AI chips and AI networking ...

Shoveling snow, especially the heavy, wet kind, can strain the heart and body and trigger serious health risks. Here’s what ...

A population-based study from Japan found that children born to mothers 35 or older were 21-41% less likely to develop food ...

Union Finance Minister Nirmala Sitharaman is all set to present the Union Budget for the financial year 2026-2027 on February ...

For investors who haven’t been living under a rock for the past year, the soaring price of gold (and other precious metals ...

Patients’ financial resources affect their enrollment in oncology clinical trials to a greater degree than traditional ...

Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...